Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Ocean Biomedical, Inc.

Get SEC filing alerts via email and in your feed for Ocean Biomedical, Inc.

OCEA OCEAW

Ocean Biomedical, Inc.

About Ocean Biomedical, Inc.

Ocean Biomedical, Inc. is a biopharmaceutical company focused on translating research discoveries from universities and medical centers into innovative therapies. Its portfolio includes preclinical programs in oncology, fibrosis, and infectious diseases, leveraging proprietary technologies and strategic licensing. The company develops targeted biologics and small molecules to address unmet medical needs, aiming for efficient, milestone-driven development and diverse commercialization pathways.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Ocean Biomedical, Inc.

1
1
Ocean Biomedical, Inc. Ocean Biomedical Reports $8.2 Million Net Loss for Q1 2025 Amid Increased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
Ocean Biomedical, Inc. Ocean Biomedical Reports $9.5 Million Net Loss for Fiscal Year 2024, Sees Improvement from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Ocean Biomedical, Inc. Ocean Biomedical Reports $5.5 Million Net Loss, Sees Decrease in Operating Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
Ocean Biomedical, Inc. Ocean Biomedical Reports Net Income Turnaround and Decreased Operating Expenses for Q1 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

5
1
Ocean Biomedical, Inc. Ocean Biomedical Reports $17.2 Million Net Loss for Q2 2024, Seeks Additional Funding

Via official filing (AI summary) | over 1 year ago | 0 comments